Linked Life Data

16807454

Source:http://linkedlifedata.com/resource/pubmed/id/16807454

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-6-29
pubmed:abstractText
Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown promising activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogues, Gemcitabine has been combined with Carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of Gemcitabine and other agents, including paclitaxel, are also feasible and have been actively studied in order to establish the role of Gemcitabine in the management of treated and untreated ovarian cancer patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1569-8041
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
17 Suppl 5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
v188-94
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Role of gemcitabine in ovarian cancer treatment.
pubmed:affiliation
Department of Oncology, Catholic University of the Sacred Heart, Campobasso, Rome, Italy.
pubmed:publicationType
Journal Article, Review, Evaluation Studies